Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24530948 | 1.00 | KDM4E (0.50) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL21300871 | 1.00 | KDM4E (0.50) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL22585010 | 1.00 | KDM4E (0.50) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL9275594 | 1.00 | KDM4E (0.50) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL21306493 | 0.85 | EPHX2 (0.43) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL27925204 | 0.82 | MAPT (0.47) | MEN1KMT2ALMNAFFAR4FFAR1 | |
| SCHEMBL23016820 | 0.82 | EPHX2 (0.41) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL25206528 | 0.82 | EPHX2 (0.41) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL515728 | 0.82 | EPHX2 (0.41) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL23234144 | 0.82 | EPHX2 (0.41) | KDM4EDUSP3MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012672-B2 | Dihydroxypropylamide-modified polysiloxane compound | DAICEL CORPORATION (JP) | 2015-04-21 | — | — | US | disclosed |
| EP-2551291-B1 | Dihydroxypropylamide-modified polysiloxane compound | DAICEL CORP (JP) | 2014-01-29 | — | — | EP | disclosed |
| US-20130030208-A1 | DIHYDROXYPROPYLAMIDE-MODIFIED POLYSILOXANE COMPOUND | DAICEL CORPORATION (JP) | 2013-01-31 | — | — | US | disclosed |
| EP-2551291-A1 | Dihydroxypropylamide-modified polysiloxane compound | Daicel Corporation (JP) | 2013-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030208-A1 | DIHYDROXYPROPYLAMIDE-MODIFIED POLYSILOXANE COMPOUND | DDOST, MRPL9, RPN2 | KDM4E 1500/4885DUSP3 4190/4885MEN1 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.